Thermo Fisher has submitted a bid for biopharmaceutical data provider CorEvitas that could value the Audax-backed company at about $1B, Bloomberg’s Michelle F. Davis and Dinesh Nair report. According to people familiar with the matter, an agreement could be announced within weeks. While other suitors are currently in the mix, Thermo Fisher is thought to be the leading bidder for CorEvitas, the report says.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on TMO:
- Looking for a Market-Beating Growth ETF? Check Out VUG
- Thermo Fisher price target lowered to $590 from $610 at Barclays
- Morgan Stanley says Elevidys label unlikely to have near-term impact on Catalent
- Avantor initiated with an Outperform at RBC Capital
- Abcam an ‘interesting candidate’ for buyout, says RBC Capital